Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17674961 | 0.92 | HSD11B1 (0.41) | HSD11B1ADORA3NR1I2PDE1APDE1B | |
| SCHEMBL21138249 | 0.86 | HSD11B1 (0.45) | HSD11B1ADORA3NR1I2 | |
| SCHEMBL21138331 | 0.84 | HSD11B1 (0.47) | HSD11B1ADORA3NR1I2 | |
| SCHEMBL21138312 | 0.84 | ADORA3 (0.46) | ADORA3PDE1APDE1BPDE1C | |
| SCHEMBL21138816 | 0.83 | HSD11B1 (0.49) | HSD11B1ADORA3NR1I2 | |
| SCHEMBL30396230 | 0.77 | HSD11B1 (0.37) | HSD11B1ADORA3NR1I2 | |
| SCHEMBL25525166 | 0.77 | HSD11B1 (0.37) | HSD11B1ADORA3NR1I2 | |
| SCHEMBL21057446 | 0.77 | HSD11B1 (0.37) | HSD11B1ADORA3NR1I2 | |
| SCHEMBL19917049 | 0.77 | HSD11B1 (0.37) | HSD11B1ADORA3NR1I2 | |
| SCHEMBL21138377 | 0.75 | HSD11B1 (0.36) | HSD11B1ADORA3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | HSD11B1 478/4885ADORA3 1484/4885NR1I2 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.